ESG News For Pfizer Inc.

Kareem Abdul-Jabbar is teaming up with Bristol Myers Squibb and Pfizer to raise awareness of atrial fibrillation (AFib) and its symptoms as part of the No Time to Wait campaign.

• Products offered on a not-for-profit basis to the 45 lower-income countries now include the full portfolio for which Pfizer has global rights.
• Expands on the initial offering of all patented medicines and vaccines available in the U.S. or EU to now include off-patent medicines, bringing total offering from 23 to around 500 products.
• Builds on already delivered medicines and vaccines along with medical training and supply chain support to Rwanda and advanced conversations with 16 other Accord country governments for supply and health system support.

The three-day event returns to fully in-person for the first time in more than three years, featuring 200+ speakers, including government officials, philanthropists, scientists, and more

Inaugural “Humankind 100” ranking celebrates companies with purpose

Alphabet scores highest in this year’s ranking

Recap of CSR stories on Business Wire

Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a live webcast at 2:30 p.m. EDT on Monday, September 26, 2022, with Caroline Roan, Chief Sustainability Officer and Senior Vice President, Global Health and Social Impact, and Louise Proud, Vice President, Environment, Health and Safety, who will discuss Pfizer’s commitment to climate action. To view and listen to the webcast, visit our web site at www.pfizer.com/investors. In addition, information on accessin

Recap of CSR stories on Business Wire

• Pfizer will provide all its current and future patent-protected medicines and vaccines available in the U.S. or EU on a not-for-profit basis to 45 lower-income countries.
• Rwanda, Ghana, Malawi, Senegal and Uganda are the first five countries to commit to join the Accord. Health officials in these countries will help identify and resolve hurdles beyond supply to inform the roll out in all 45 lower-income countries.
• Pfizer calls upon global health leaders and organizations to join the Accord, bringing their expertise and resources to close the health equity gap and help create a healthier world for 1.2 billion people.

Supporting Cambridge's Life Sciences Ecosystem: Q With James Seppala and Tim Schoen Tue, 04/05/2022 - 10:15 Subheader James Seppala and Tim Schoen discuss BioMed Realty’s footprint in the UK and the opportunity in the life sciences real estate market in the years ahead. Type of Content Blog Layout Media Gallery Body Fueled by rapid innovation and rising demand, the global life sciences industry has seen significant growth over the last decade. At Blackstone, life sciences have become one of our

Three of nine companies facing upcoming investor votes on median pay gap data this proxy season commit to disclosure. Disney fails to block investors from voting on matter.

For the five and a half billion people around the world who have so far received a COVID-19 vaccine, the FDA’s 2021 approval of Pfizer-BioNTech’s offering may not seem like a big deal.

AIDS Healthcare Foundation (AHF) praised today Merck and Ridgeback Biotherapeutics for granting a royalty-free license to manufacture their COVID-19 antiviral drug molnupiravir in more than 100 developing countries. AHF calls on Moderna, Pfizer, and Johnson & Johnson to follow Merck’s example and voluntarily grant royalty-free manufacturing and distribution rights for their COVID-19 vaccines and facilitate technology transfers to expand generic vaccine production around the world. “If Merck

Today the Centers for Disease Control and Prevention (CDC) concurred with previous recommendations made by the Food and Drug Administration (FDA) and the Advisory Committee on Immunization Practices (ACIP), officially recommending “booster” doses of the Pfizer-BioNTech COVID-19 vaccine for certain eligible populations at least 6 months after the second dose of the Pfizer-BioNTech COVID-19 vaccine. As a proud partner in the Federal Retail Pharmacy Program, Rite Aid is prepared to begin administer

AHF is encouraged by President Biden’s announcements regarding global vaccination but cautions dramatic, game changing action is required to vaccinate our world

Bahar's recent research takes a look at the ESG data on each of the vaccine manufactures: Moderna Inc. Pfizer Inc., and Johnson & Johnson.

• Expanded agreement brings the total number of COVID-19 vaccine doses to be supplied to the U.S. government for donation to one billion
• Effort contributes to companies’ pledge to deliver two billion COVID-19 vaccine doses to low- and middle-income countries by the end of 2022

SOURCE: CSRHub DESCRIPTION:As previously seen on Skytop and published with permission. Many of us have recently pondered the question: which vaccine is better—Pfizer, Moderna, or JJ? Those of us interested in sustainability may also want to know which of these companies has the best ESG (Environment, Social, Governance) performance? CSRHub’s ESG ratings service tracks all three companies (we currently track more than 45,000 entities). All three companies have above average ratings. All Three Comp

9/11 Day 2021 PSA campaign State of Unitedness calls upon all Americans to join together in unity for the 20-year remembrance of 9/11.

After successful pilot with University of Wisconsin-Milwaukee, call for applications opens globally

Working with Skytop Strategies, CSRHub took a look at the ESG data on the three major Covid-19 vaccine manufactures

SOURCE: CSRHub DESCRIPTION:Those interested in sustainability should be interested in a different way of comparing the major vaccines. Vaccine-producing companies have made huge contributions to fighting the COVID plague. They have spent millions of dollars developing and manufacturing products that have only moderate financial benefit, but deliver big social value. Working with Skytop Strategies, CSRHub took a look at the ESG data on three major vaccine manufactures. Our article digs below the t

Grocer continues disaster relief partnership with American Red Cross with $250,000 donation

Goal Setting and Measurement report finds decarbonization strategies are increasingly complex and current solutions may not be enough to achieve aggressive targets SOURCE: Black Veatch DESCRIPTION:May 11, 2021 /3BL Media/ - Companies of all sizes across business sectors are elevating sustainability as a core tenet of their practices, yet a new Black Veatch report discovers that many companies continue to establish targets without a clear understanding of how to achieve them. Black Veatch’s Corpor

Partnership with MetroHealth Aims to Vaccinate in Neighborhoods with Lowest Vaccine Rate

CR Forum Bestows Additional Honors to Outstanding Clinical Research Organizations for Groundbreaking Clinical and Translational Research Advancements with 2021 Top 10 Clinical Research Achievement Awards

Long Island Jewish Medical Center nurse Sandra Lindsay’s historic first Pfizer-BioNTech vaccine will now be part of National Museum of American History Collections

Sponsors Women in Data and Women in Revenue;

Debuts special edition of Women Who Catalog Event featuring Parexel CDO, Michelle Hoiseth

Company Celebrates Migrants in Honor of International Migrants Day

SOURCE: Novartis DESCRIPTION:September 30, 2020 /3BL Media/ - COVID-19’s existence anywhere poses a threat to communities everywhere. The health, social, and economic impacts can only be addressed through the collective actions of stakeholders across private, public, and philanthropic sectors in partnership with civil society. As organizations dedicated to improving and protecting global health, with our varied skills, roles, and resources, we remain committed to doing our part in ending this pan

• Funding to Support Development of New Antibiotics as Part of Broader Industry Effort
• New Partnership with More than 20 Other Companies Will Focus on Medicines that Address Most Resistant Bacteria and Life-Threatening Infections
• Builds on Pfizer’s longstanding work to address the global burden of infectious diseases

L'American Cancer Society (ACS) et la Clinton Health Access Initiative (CHAI) ont annoncé aujourd'hui des accords avec les sociétés pharmaceutiques Pfizer, Novartis et Mylan pour élargir l'accès à 20 traitements anticancéreux vitaux dans 26 pays d'Afrique Subsaharienne et d'Asie. Les patients devraient économiser en moyenne 59 % sur les médicaments achetés dans le cadre de ces accords.

The American Cancer Society (ACS) and the Clinton Health Access Initiative (CHAI) today announced agreements with pharmaceutical companies Pfizer, Novartis, and Mylan to expand access to 20 lifesaving cancer treatments in 26 countries in sub-Saharan Africa and Asia. Purchasers are expected to save an average of 59 percent for medicines procured through the agreements.

Recap of CSR stories on Business Wire

• Antimicrobial resistance is a leading global health challengeⁱ that requires urgent action to ensure a safer world for everyone, everywhere
• Effective surveillance and timely data feedback are critical for infection prevention and control programs, and informing appropriate use of anti-infectives
• New partnership in Ghana, Kenya, Malawi and Uganda will provide governments and public health community with critical decision-making information to help address AMR

A state-of-the-art facility allowing Pfizer Inc. to significantly expand its global clinical manufacturing and speed critical therapies to patients has been awarded the 2020 Facility of the Year Award for Facility Integration

ViiV HC announces £3 million global fund to research the impact of COVID-19 on the HIV community and fill gaps in prevention, treatment, and care

Recap of CSR stories on Business Wire

Pfizer Inc. (NYSE: PFE) and The Pfizer Foundation today announced the commitment of $40 million in medical and charitable cash grants to help combat the global health effects of the COVID-19 pandemic in the U.S. and around the world.

• Building on Pfizer’s longstanding commitment to fight infectious diseases, grants will help address urgent needs of U.S. and global partners on the front lines of the pandemic
• Donations complement Pfizer’s COVID-19 R&D investments, as well as collective scientific and philanthropic contributions made by the biopharmaceutical industry
• U.S. Patient Assistance Program and other programs respond to changing needs of patients and medical community

Three leading biopharmaceutical companies have announced programs enabling employees with medical and laboratory expertise to volunteer their services to local healthcare systems and those hardest hit by COVID-19.

Collaboration to address product development and scale up challenges posed by current pandemic SOURCE: Novartis DESCRIPTION:BASEL, Switzerland, March 26, 2020/3BL Media/ - Today, Novartis and a consortium of life sciences companies announced an important collaboration to accelerate the development, manufacture and delivery of vaccines, diagnostics, and treatments for COVID-19 in response to the pandemic. The industry brings a range of assets, resources, and expertise needed to identify effective

Safe Medication Kiosk Program now offering nearly 1,500 kiosks nationwide

Overdose antidote Narcan available without a prescription in all Walgreens U.S. pharmacies

Today on International Day of Rural Women, Pfizer is reflecting on its work with partners – including CARE, International Rescue Committee, Save the Children and World Vision – to strengthen health systems and empower women in rural areas.

African Americans are disproportionately affected by many diseases and Pfizer is committed to improving health among this segment of the population through science, partnerships, insights and expertise.

Recap of CSR stories on Business Wire

The Pfizer Foundation* announced today 20 grants to help non-governmental organizations (NGOs), non-profits and social enterprises address critical health challenges related to infectious diseases...

Grants to help strengthen health systems and reduce health disparities in underserved communities in Africa, Asia and Latin America

At Pfizer, we discover and develop novel vaccines that help protect people around the world from deadly viruses and bacteria.

Pfizer is committed to ensuring that the manufacturing, use and disposal of our products, including antibiotics, does not adversely affect human health or the environment. Core to this commitment is taking action to assess and reduce, as needed, the risk of antibiotics in wastewater from Pfizer and supplier manufacturing facilities

Our approach to global health challenges unleashes the full power of our resources to help strengthen healthcare systems and increase access for the most vulnerable people around the world.